研究

前田　英紀（マエダヒデキ）

所属
臨床薬学部門/レギュラトリーサイエンス
職位
教授
学位
博士（薬科学）

主な研究業績

  • Gender differences in pharmacy professors in Japan and Korea.

    Maeda H, Soh H, Hashimoto M, Han E, Ohno E.

    Lancet Reg Health West Pac. 2025 Jan 15;54:101469. doi: 10.1016/j.lanwpc.2025.101469.

  • Cross-sectional Study and Comparison between Japan and the United States on Special Regulatory Pathways for Expedited Drug Development and Approval.

    Kobayashi K, Inaba Y, Hashimoto M, Maeda H.

    Therapeutic Innovation & Regulatory Science. 2025. https://doi.org/10.1007/s43441-025-00771-5.

  • Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis.

    Nakatani S, Hayashi T, Yamamoto K, Maeda H.

    Cancer Treatment Reviews. 2025. 135: 102923.

  • Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.

    Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y.

    Clin Transl Sci. 2023 Dec;16(12):2665-2674. doi: 10.1111/cts.13660.

  • Comparison of the Speed of Enrollment for Clinical Trials Conducted by Japanese and Global Pharmaceutical Companies.

    Maeda H, Yamanoi M, Fukuda Y, Inaba Y.

    Biol Pharm Bull. 2023; 46(9): 1289-1295. e238875. doi: https://doi.org/10.1248/bpb.b23-00245

  • Assessment of Surrogate End Point Trends in Clinical Trials to Approve Oncology Drugs From 2001 to 2020 in Japan.

    Maeda H, Shingai R, Takeda K, Hara A, Murai Y, Ofuchi M.

    JAMA Netw Open. 2023 Apr 3;6(4):e238875. doi:10.1001/jamanetworkopen.2023.8875.

  • Comparison of regulatory approval system for medicines in emergency among Japan, the United States, the United Kingdom, Europe, and China.

    Edo K, Kawano M, Maeda H.

    PLoS One. 2024. 19(9): e0309992. https://doi.org/ 10.1371/journal.pone.0309992.

  • Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan.

    Mochizuki M, Maeda H.

    Front Med Technol. 2024 Aug 6;6:1461460. doi: 10.3389/fmedt.2024.

  • A qualitative interview study on expanded access clinical trials for compassionate use in Japan.

    Hayashi H, Nogita T, Maeda H.

    Patient Preference and Adherence. 2024 Jul 11;18:1471-1479. doi: 10.2147/PPA.S468663.

  • Current situation and issues regarding termination of risk management plans in Japan.

    Kameyama N, Hosaka A, Maeda H.

    Front Med. 2024 May 30;11:1387652. doi: 10.3389/fmed.2024.1387652.

  • Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review.

    Hiramatsu K, Maeda H.

    Clin Transl Sci. 2024 May;17(5):e13794. doi: 10.1111/cts.13794.

所属学協会

  • ASCO (American Society of Clinical Oncology)
  • ASCPT (American Society for Clinical Pharmacology and Therapeutics)
  • 日本薬学会
  • レギュラトリーサイエンス学会
  • 日本薬史学会
  • 日本臨床薬理学会
  • 日本医療薬学会
  • 日本臨床腫瘍学会
  • 日本癌治療学会
  • Drug Information Association (DIA)
  • 抗悪性腫瘍薬開発フォーラム
  • 日本薬剤疫学会

研究者情報の詳細は
researchmap をご覧ください。

Recommendations

おすすめコンテンツ

TOP